Dexlansoprazole Capsule, Delayed Release
Product Images NDC 46708-824

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Dexlansoprazole (NDC 46708-824). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dexlansoprazole-30-mg-capsule (Dexlansoprazole 30 mg Capsule)

Dexlansoprazole-30-mg-capsule (Dexlansoprazole 30 mg Capsule)
Each capsule contains 30 mg of dexlansoprazole as enteric coated pellets. The usual dosage is provided in the package insert. Store at room temperature between 15°C to 30°C (59°F to 86°F) as per USP Controlled Capsules guidelines. It is recommended not to use if the seal is broken or missing. The package is child-resistant. A medication guide should be dispensed to each patient by PHARNACH. Manufactured by Alembic Pharmaceuticals Limited in Gujarat, India. 30 capsules in the pack. Rx only.*
FDA Label Image

Dexlansoprazole-60-mg-capsule (Dexlansoprazole 60 mg Capsule)

Dexlansoprazole-60-mg-capsule (Dexlansoprazole 60 mg Capsule)
Each capsule contains 60 mg of dexlansoprazole as enteric coated pellets. The usual dosage can be found in the package insert. Store at 25°C (77°F) with excursions permitted to 15° to 30°C (59° to 86°F) according to USP Controlled Room Temperature guidelines. Do not accept if seal over the bottle opening is broken or missing. The package is child-resistant. Manufactured by Alembic Pharmaceuticals Limited in Gujarat, India. The product is Dexlansoprazole Delayed-Release Capsules, with 30 capsules in a prescription. The pharmacist is advised to dispense the accompanying Medication Guide to each patient. The manufacturing license number is G/25/2315. Lot and expiry date of the product are indicated as 11/2025.*
FDA Label Image

Dexlansoprazole-fig1.jpg (Dexlansoprazole Fig1)

Dexlansoprazole-fig1.jpg (Dexlansoprazole Fig1)
This text provides information on plasma concentration (in ng/mL) of Dexlansoprazole at two different dosages: 30 mg and 60 mg. The graph displays the concentrations over a period of time.*
FDA Label Image

Dexlansoprazole-str.jpg (Dexlansoprazole Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.